[anaisbetts]

> Leave the diabetes drugs alone.

Is artificially partitioning what is almost certainly the same medication (with the same manufacturing process) into two separate product lines actually a Good Thing? This means that when Mounjaro has supply problems even with the split, diabetics won't be able to get it because part of the supply is inaccessible to them since it is dedicated to a different "product".

Instead we should advocate for the real solution, which is to demand the manufacturer drastically increase production - Mounjaro along with Semaglutide have literally capital-S Solved one of the most urgent health epidemics of the 21st century, and the solution isn't to shame people for using it, the solution is to make it available to anyone who needs it.

[bedast]

Significantly increasing production for a temporary benefit is going to require significant investment. Since it is a temporary benefit, it's probably not worth that significant investment. Because eventually the demand will falter.

And yeah, the weight loss benefit is a temporary benefit. It may last a few years, but it fades. This is not a new drug class. The weight loss aspect to it is also not new (Saxenda, the weight loss variant of Victoza, released in 2014). Liraglutide was in trials for weight management when I started Victoza. That was a decade ago. I'm on Mounjaro now for glycemic management and it works great for that. But it's not doing anything for appetite, delayed gastric emptying, etc.

[MichaelZuo]

Who is this 'we'?

I'm quite certain a large fraction of the HN userbase still believes that people can do independent business without being forced along one direction or another.

[anaisbetts]

What in the world are you talking about

[MichaelZuo]

> Instead we should advocate for the real solution, which is to demand the manufacturer drastically increase production -